Information:
Fel:
ID
45513
Beskrivning
Principal Investigator: Sami N. Malek, MD, University of Michigan Department of Internal Medicine, Division of Hematology-Oncology, Ann Arbor, MI, USA MeSH: Lymphoma, Follicular,Lymphoma, Non-Hodgkin https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000729 A cohort of follicular lymphoma cases had tumor cells purified from tissue samples after informed consent using flow cytometry. DNA was extracted from the cells, and samples were subjected to solution-based exome capture using the Illumina TruSeq Exome Enrichment Kit and the Illumina HiSeq 2000 platform.
Länk
Nyckelord
Versioner (1)
- 2022-12-13 2022-12-13 - Simon Heim
Rättsinnehavare
Sami N. Malek, MD, University of Michigan Department of Internal Medicine, Division of Hematology-Oncology, Ann Arbor, MI, USA
Uppladdad den
13 december 2022
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs000729 Follicular Lymphoma 2013 - Malek
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, disease diagnosis, age onset, and sex of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of cancer, and method for tumor and normal cell purification of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, disease diagnosis, age onset, and sex of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of cancer, and method for tumor and normal cell purification of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
C0680251 (UMLS CUI [1,2])
Patients were enrolled between 2008 and 2012 into a lymphoma repository at the University of Michigan Comprehensive Cancer Center. The study procured patient material during times of clinically indicated lymphoma surgeries. This study also procured buccal swabs, peripheral blood and occasional bone marrow aspirates. Subclassifications of the follicular lymphomas by World Health Organization criteria were verified by a hematopathologist using histopathologic, cytologic, and immunophenotypic features.
Item
Patients were enrolled between 2008 and 2012 into a lymphoma repository at the University of Michigan Comprehensive Cancer Center. The study procured patient material during times of clinically indicated lymphoma surgeries. This study also procured buccal swabs, peripheral blood and occasional bone marrow aspirates. Subclassifications of the follicular lymphomas by World Health Organization criteria were verified by a hematopathologist using histopathologic, cytologic, and immunophenotypic features.
boolean
C0030705 (UMLS CUI [1,1])
C1512693 (UMLS CUI [1,2])
C0024299 (UMLS CUI [1,3])
C3847505 (UMLS CUI [1,4])
C1519799 (UMLS CUI [1,5])
C0392360 (UMLS CUI [1,6])
C0543467 (UMLS CUI [1,7])
C0200345 (UMLS CUI [1,8])
C0005954 (UMLS CUI [1,9])
C0229664 (UMLS CUI [1,10])
C0580344 (UMLS CUI [1,11])
C0024301 (UMLS CUI [1,12])
C0008902 (UMLS CUI [1,13])
C1301142 (UMLS CUI [1,14])
C1711411 (UMLS CUI [1,15])
C0334866 (UMLS CUI [1,16])
C1265900 (UMLS CUI [1,17])
C0428093 (UMLS CUI [1,18])
C4745253 (UMLS CUI [1,19])
C1512693 (UMLS CUI [1,2])
C0024299 (UMLS CUI [1,3])
C3847505 (UMLS CUI [1,4])
C1519799 (UMLS CUI [1,5])
C0392360 (UMLS CUI [1,6])
C0543467 (UMLS CUI [1,7])
C0200345 (UMLS CUI [1,8])
C0005954 (UMLS CUI [1,9])
C0229664 (UMLS CUI [1,10])
C0580344 (UMLS CUI [1,11])
C0024301 (UMLS CUI [1,12])
C0008902 (UMLS CUI [1,13])
C1301142 (UMLS CUI [1,14])
C1711411 (UMLS CUI [1,15])
C0334866 (UMLS CUI [1,16])
C1265900 (UMLS CUI [1,17])
C0428093 (UMLS CUI [1,18])
C4745253 (UMLS CUI [1,19])